先进药物筛检技术市场分析及预测（至2035年）：依类型、产品、技术、应用、形式、设备、製程、最终用户及阶段划分

预计到2034年，先进药物筛检技术市场规模将从2024年的77亿美元成长至134亿美元，复合年增长率约为6.3%。该市场涵盖用于评估药物疗效和安全性的创新调查方法，例如高通量筛检、基于细胞的检测和In Silico模拟。这些技术透过提高准确性和缩短筛检週期来加速药物发现过程。推动市场成长的因素包括：对个人化医疗日益增长的需求、技术进步以及对药物研发投入的不断增加，这些因素共同促进了药物研发过程的成长和创新。

受创新药物发现方法迫切需求的推动，先进药物筛检技术市场正经历强劲成长。基于细胞的检测方法因其能够提供更生理相关性的数据，成为成长最快的细分市场。该细分市场受益于3D细胞培养技术的进步，从而提高了预测准确性。高通量筛检（HTS）是表现第二好的细分市场，这得益于其能够快速且有效率地测试大规模库。在HTS领域，自动化机器人系统日益普及，显着提升了筛选速度和准确性。生化检测方法也值得关注，尤其是酵素学检测，它对于识别活性化合物至关重要。将人工智慧（AI）和机器学习技术融入筛检流程正成为优化数据分析和决策的变革性趋势。对个人化医疗的需求正在推动这些先进技术的应用，从而支撑着市场巨大的成长和创新潜力。

先进药物筛检技术市场产品种类繁多，主要厂商不断推出创新解决方案，以满足日益增长的高效筛检方法需求。定价策略因地区而异，并受当地市场趋势和竞争压力的影响。快速药物发现和开发的需求正推动市场转型为更具成本效益的高通量筛检技术。新兴市场对这些先进技术的应用尤其强劲，这主要得益于不断增长的医药投资和政府的支持政策。先进药物筛检技术市场的竞争异常激烈，各公司都在寻求透过技术创新和策略联盟来实现差异化。监管影响至关重要，北美和欧洲严格的监管准则塑造竞争格​​局。基准研究表明，投资自动化和人工智慧驱动解决方案的公司正在获得竞争优势。个人化医疗和生物技术的进步正在推动市场需求，预计市场将显着成长。儘管监管合规和高昂的初始成本等挑战依然存在，但提高药物疗效和安全性的潜力为相关人员提供了盈利的机会。

主要趋势和驱动因素：

由于对个人化医疗和标靶治疗的需求不断增长，先进药物筛检技术市场正经历强劲成长。关键趋势包括将人工智慧 (AI) 和机器学习相结合，以提高筛检的准确性和效率。这些技术加速了药物发现过程，缩短了新疗法的上市时间。此外，慢性病盛行率的上升以及对创新治疗方案的需求也推动了市场扩张。高通量筛检技术的进步是推动市场成长的主要因素，这些技术能够快速分析大型化合物库。这种能力对于识别有前景的候选药物至关重要。此外，降低药物研发成本和提高临床试验成功率的日益增长的需求也推动了先进筛检方法的应用。监管机构对创新药物开发方法的支持也促进了市场成长。新兴市场拥有完善的医疗基础设施和不断成长的研发投入，蕴藏着许多机会。提供全面筛检解决方案并利用最尖端科技的公司有望占据显着的市场份额。製药公司与研究机构之间开放式创新和合作的趋势进一步促进了药物筛检技术的进步。随着对高效药物发现流程的需求持续增长，预计该市场将继续扩张。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

• 宏观经济分析
• 市场趋势
• 市场驱动因素
• 市场机会
• 市场限制
• 复合年均成长率：成长分析
• 影响分析
• 新兴市场
• 技术蓝图
• 战略框架

第四章 细分市场分析

• 市场规模及预测：依类型
  • 生化筛检
  • 基于细胞的检测
  • In Silico筛检
• 市场规模及预测：依产品划分
  • 试剂和耗材
  • 装置
  • 软体和服务
• 市场规模及预测：依技术划分
  • 高通量筛检
  • 超高通量筛检
  • 自动化液体处理
• 市场规模及预测：依应用领域划分
  • 製药和生物技术公司
  • 学术和研究机构
  • 受託研究机构
• 市场规模及预测：依类型
  • 固相
  • 液相
• 市场规模及预测：依设备划分
  • 微孔盘读数仪
  • 自动化系统
• 市场规模及预测：依製程划分
  • 铅识别
  • 先导药物最适化
  • 目标识别
• 市场规模及预测：依最终用户划分
  • 医院
  • 诊断检查室
  • 研究中心
• 市场规模及预测：依阶段划分
  • 药物发现
  • 临床前
  • 临床

第五章 区域分析

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲地区
• 亚太地区
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲
  • 台湾
  • 亚太其他地区
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 义大利
  • 其他欧洲地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非
  • 撒哈拉以南非洲
  • 其他中东和非洲地区

第六章 市场策略

• 需求与供给差距分析
• 贸易和物流限制
• 价格、成本和利润率趋势
• 市场渗透率
• 消费者分析
• 法规概述

第七章 竞争讯息

• 市场定位
• 市场占有率
• 竞争基准
• 主要企业的策略

第八章：公司简介

• Bio-Rad Laboratories
• Charles River Laboratories
• Perkin Elmer
• Eurofins Scientific
• Qiagen
• Agilent Technologies
• Thermo Fisher Scientific
• Evotec
• Illumina
• Promega Corporation
• Merck KGa A
• GE Healthcare
• Danaher Corporation
• Bruker Corporation
• Waters Corporation
• Shimadzu Corporation
• Bio-Techne
• Abcam
• Cell Signaling Technology
• Sartorius AG

第九章：关于我们

Advanced Drug Screening Techniques Market is anticipated to expand from $7.7 billion in 2024 to $13.4 billion by 2034, growing at a CAGR of approximately 6.3%. The Advanced Drug Screening Techniques Market encompasses innovative methodologies for evaluating drug efficacy and safety, including high-throughput screening, cell-based assays, and in silico modeling. These techniques accelerate drug discovery by enhancing precision and reducing development timelines. The market is driven by rising demand for personalized medicine, technological advancements, and increased investment in pharmaceutical R&D, fostering growth and innovation in drug development processes.

The Advanced Drug Screening Techniques Market is experiencing robust growth, fueled by the urgent need for innovative drug discovery methods. The cell-based assays segment is the top-performing sub-segment, driven by its ability to provide more physiologically relevant data. This segment benefits from advancements in 3D cell culture technologies, enhancing predictive accuracy. High-throughput screening (HTS) follows as the second highest-performing sub-segment, owing to its efficiency in rapidly testing large compound libraries. Within HTS, automated robotic systems are gaining prominence, offering increased speed and precision. The biochemical assays segment is also notable, especially in enzymatic assays, which are crucial for identifying active compounds. The integration of artificial intelligence and machine learning in screening processes is emerging as a transformative trend, optimizing data analysis and decision-making. The demand for personalized medicine is propelling the adoption of these advanced techniques, underscoring the market's potential for substantial growth and innovation.

The Advanced Drug Screening Techniques Market is characterized by a diverse array of product offerings, with several key players consistently launching innovative solutions to meet the growing demand for efficient screening methods. Pricing strategies vary significantly across regions, influenced by local market dynamics and competitive pressures. The market is seeing a shift towards more cost-effective and high-throughput screening technologies, driven by the need for rapid drug discovery and development. Emerging markets are particularly active in adopting these advanced techniques, spurred by increased pharmaceutical investments and supportive governmental policies. Competition within the Advanced Drug Screening Techniques Market is intense, with companies striving to differentiate through technological innovation and strategic partnerships. Regulatory influences play a pivotal role, with stringent guidelines in North America and Europe shaping the competitive landscape. Benchmarking indicates that firms investing in automation and AI-driven solutions are gaining a competitive edge. The market is poised for significant growth, with advancements in personalized medicine and biotechnology driving demand. Challenges such as regulatory compliance and high initial costs remain, yet the potential for enhanced drug efficacy and safety offers lucrative opportunities for stakeholders.

Geographical Overview:

The advanced drug screening techniques market is witnessing notable expansion across various regions, each presenting unique growth opportunities. North America leads, driven by technological advancements and a strong focus on drug discovery and development. Major pharmaceutical companies invest heavily in innovative screening technologies, bolstering the region's market position. Europe follows closely, with a robust regulatory framework and significant investments in research and development, fostering a conducive environment for market growth. The Asia Pacific region is rapidly emerging, propelled by increasing healthcare expenditure and the presence of numerous contract research organizations. Countries like China and India are at the forefront, offering cost-effective solutions and a skilled workforce. Latin America and the Middle East & Africa are nascent markets with promising potential. In Latin America, Brazil and Mexico are witnessing increased investments in healthcare infrastructure. Meanwhile, the Middle East & Africa region is recognizing the importance of advanced drug screening techniques in enhancing healthcare outcomes and driving innovation.

The Advanced Drug Screening Techniques Market is intricately affected by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, the emphasis is on enhancing domestic capabilities to mitigate reliance on foreign technologies amidst escalating trade tensions. China, confronted with export barriers, is accelerating its investment in homegrown drug screening technologies to ensure self-sufficiency. Taiwan remains pivotal due to its advanced manufacturing prowess but is vulnerable to cross-strait tensions. Globally, the market is robust, driven by technological advancements and increasing healthcare demands. By 2035, the market is anticipated to flourish, contingent on strategic regional collaborations and resilient supply chains. Middle East conflicts pose a potential threat to energy prices, indirectly affecting operational costs and supply chain stability in the sector.

Key Trends and Drivers:

The Advanced Drug Screening Techniques Market is experiencing robust growth due to the rising demand for personalized medicine and targeted therapies. Key trends include the integration of artificial intelligence and machine learning to enhance screening accuracy and efficiency. These technologies enable faster drug discovery processes, reducing time-to-market for new therapies. Additionally, the increasing prevalence of chronic diseases and the need for innovative treatment solutions are propelling market expansion. Drivers of this market include advancements in high-throughput screening technologies, which allow for the rapid analysis of large compound libraries. This capability is crucial in identifying promising drug candidates. Furthermore, the growing focus on reducing drug development costs and improving success rates in clinical trials is encouraging the adoption of advanced screening methods. Regulatory support for innovative drug development approaches is also fostering market growth. Opportunities abound in emerging markets where healthcare infrastructure is improving, and investment in R&D is increasing. Companies that offer comprehensive screening solutions and leverage cutting-edge technologies are well-positioned to capture significant market share. The trend towards open innovation and collaboration among pharmaceutical companies and research institutions is further driving advancements in drug screening techniques. As the demand for effective and efficient drug discovery processes continues to grow, the market is set for sustained expansion.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by Form
• 2.6 Key Market Highlights by Device
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by End User
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Biochemical Screening
  • 4.1.2 Cell-based Assays
  • 4.1.3 In Silico Screening
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Reagents & Consumables
  • 4.2.2 Instruments
  • 4.2.3 Software & Services
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 High-Throughput Screening
  • 4.3.2 Ultra-High-Throughput Screening
  • 4.3.3 Automated Liquid Handling
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Pharmaceutical & Biotechnology Companies
  • 4.4.2 Academic & Research Institutes
  • 4.4.3 Contract Research Organizations
• 4.5 Market Size & Forecast by Form (2020-2035)
  • 4.5.1 Solid Phase
  • 4.5.2 Liquid Phase
• 4.6 Market Size & Forecast by Device (2020-2035)
  • 4.6.1 Microplate Readers
  • 4.6.2 Automated Systems
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Lead Identification
  • 4.7.2 Lead Optimization
  • 4.7.3 Target Identification
• 4.8 Market Size & Forecast by End User (2020-2035)
  • 4.8.1 Hospitals
  • 4.8.2 Diagnostic Laboratories
  • 4.8.3 Research Centers
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Discovery
  • 4.9.2 Preclinical
  • 4.9.3 Clinical

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 Form
    • 5.2.1.6 Device
    • 5.2.1.7 Process
    • 5.2.1.8 End User
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 Form
    • 5.2.2.6 Device
    • 5.2.2.7 Process
    • 5.2.2.8 End User
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 Form
    • 5.2.3.6 Device
    • 5.2.3.7 Process
    • 5.2.3.8 End User
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 Form
    • 5.3.1.6 Device
    • 5.3.1.7 Process
    • 5.3.1.8 End User
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 Form
    • 5.3.2.6 Device
    • 5.3.2.7 Process
    • 5.3.2.8 End User
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 Form
    • 5.3.3.6 Device
    • 5.3.3.7 Process
    • 5.3.3.8 End User
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 Form
    • 5.4.1.6 Device
    • 5.4.1.7 Process
    • 5.4.1.8 End User
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 Form
    • 5.4.2.6 Device
    • 5.4.2.7 Process
    • 5.4.2.8 End User
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 Form
    • 5.4.3.6 Device
    • 5.4.3.7 Process
    • 5.4.3.8 End User
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 Form
    • 5.4.4.6 Device
    • 5.4.4.7 Process
    • 5.4.4.8 End User
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 Form
    • 5.4.5.6 Device
    • 5.4.5.7 Process
    • 5.4.5.8 End User
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 Form
    • 5.4.6.6 Device
    • 5.4.6.7 Process
    • 5.4.6.8 End User
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 Form
    • 5.4.7.6 Device
    • 5.4.7.7 Process
    • 5.4.7.8 End User
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 Form
    • 5.5.1.6 Device
    • 5.5.1.7 Process
    • 5.5.1.8 End User
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 Form
    • 5.5.2.6 Device
    • 5.5.2.7 Process
    • 5.5.2.8 End User
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 Form
    • 5.5.3.6 Device
    • 5.5.3.7 Process
    • 5.5.3.8 End User
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 Form
    • 5.5.4.6 Device
    • 5.5.4.7 Process
    • 5.5.4.8 End User
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 Form
    • 5.5.5.6 Device
    • 5.5.5.7 Process
    • 5.5.5.8 End User
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 Form
    • 5.5.6.6 Device
    • 5.5.6.7 Process
    • 5.5.6.8 End User
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 Form
    • 5.6.1.6 Device
    • 5.6.1.7 Process
    • 5.6.1.8 End User
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 Form
    • 5.6.2.6 Device
    • 5.6.2.7 Process
    • 5.6.2.8 End User
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 Form
    • 5.6.3.6 Device
    • 5.6.3.7 Process
    • 5.6.3.8 End User
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 Form
    • 5.6.4.6 Device
    • 5.6.4.7 Process
    • 5.6.4.8 End User
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 Form
    • 5.6.5.6 Device
    • 5.6.5.7 Process
    • 5.6.5.8 End User
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Bio- Rad Laboratories
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Charles River Laboratories
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Perkin Elmer
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Eurofins Scientific
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Qiagen
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Agilent Technologies
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Thermo Fisher Scientific
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Evotec
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Illumina
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Promega Corporation
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Merck KGa A
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 GE Healthcare
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Danaher Corporation
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Bruker Corporation
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Waters Corporation
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Shimadzu Corporation
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Bio- Techne
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Abcam
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Cell Signaling Technology
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Sartorius AG
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us